New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:34 EDTVIVOMeridian receives Canadian licenses for two illumigene platforms
Meridian Bioscience announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing solutions that meet the needs of the clinical laboratory and drive improvements in patient care.
News For VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 26, 2015
08:46 EDTVIVOMeridian Bioscience receives CE Mark for streptococcus pneumoniae test
Meridian Bioscience announces that it has received the CE Mark for its new test for Streptococcus pneumoniae. TRU STREP PNEUMO is a rapid, qualitative immunoassay for the detection of S. pneumo antigen in urine and CSF and will be distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the company’s global distribution network.
08:38 EDTVIVOMeridian Bioscience receievs CE mark for two molecular amplification tests
Meridian Bioscience announced that it has received the CE Mark for two new molecular diagnostic tests for Chlamydia trachomatis and Neisseria gonorrhoeae, the sixth and seventh assays on the illumigene platform. Along with these two new assays, Meridian also received the CE Mark for an innovative, simple, fast and cost effective sample preparation system, M-prep, that is designed to facilitate the isolation of Chlamydia and Gonorrhoeae from clinical samples. All three products will be distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the company’s global distribution network.
08:33 EDTVIVOMeridian Bioscience receives CE Mark for chlamydia, gonorrhoeae tests
Meridian Bioscience announced that it has received the CE Mark for two new molecular diagnostic tests for Chlamydia trachomatis and Neisseria gonorrhoeae, the sixth and seventh assays on the illumigene platform. Along with these two new assays, Meridian also received the CE Mark for a sample preparation system, M-prep, that is designed to facilitate the isolation of Chlamydia and Gonorrhoeae from clinical samples. All three products will be distributed in the EMEA regions by Meridian Bioscience Europe and in additional international markets by the company’s global distribution network.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use